BriaCell Therapeutics Corp. (BCTX) Income from Non-Controlling Interests (2023 - 2026)

BriaCell Therapeutics has reported Income from Non-Controlling Interests for 4 years, with the latest figure at -$72548.0 in Q2 2026.

• Quarterly Income from Non-Controlling Interests rose 25.99% year-over-year to -$72548.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$301121.0 (down 46.09% YoY) and the FY2025 annual result came in at -$244273.0, down 74.38% from the prior year.
• Income from Non-Controlling Interests grew to -$72548.0 in Q2 2026 per BCTX's latest filing, from -$75073.0 in the prior quarter.
• Over five years, Income from Non-Controlling Interests peaked at -$23517.0 in Q2 2024 and troughed at -$98027.0 in Q2 2025.
• A 4-year average of -$55703.5 and a median of -$46408.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
• The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests soared 36.49% in 2024, then sank 316.83% in 2025.
• Over 4 years, Income from Non-Controlling Interests stood at -$42671.0 in 2023, then jumped by 36.49% to -$27101.0 in 2024, then tumbled by 198.01% to -$80763.0 in 2025, then gained by 10.17% to -$72548.0 in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$72548.0, -$75073.0, and -$80763.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.